Back to search

Boston University

Topical use of monoclonal antibodies as a multipurpose prevention technology offering contraception and decreased transmission of HIV-1 and trichomonas vaginalis

Abstract

dc:description.abstract

New transgenic antibody production platforms enable cost-effective, rapid manufacturing of antibodies for clinical applications. Our lab is investigating a human monoclonal antibody, the Human Contraceptive Antibody (HCA), produced in Nicotiana benthamiana, as a candidate for a topical Multipurpose Prevention Technology offering both contraception and protection against sexually transmitted infections. HCA was developed from a sperm-agglutinating antibody isolated from plasma cells of an infertile woman. The antibody targets a GPI-anchored glycoprotein, CD52g, produced specifically by epithelial cells in the male reproductive tract (MRT). Due to its GPI anchor, the hypermobile protein coats sperm as they migrate through the MRT. In this study, we tested HCA’s specificity and contraceptive properties under physiologically relevant conditions in vitro. We demonstrated that HCA quickly and potently agglutinates sperm in physiological conditions at concentrations >6.25 μg/mL. Sperm concentration, soluble CD52g found in seminal plasma/whole semen, or prolonged exposure to the low pH found in the vaginal tract did not affect agglutination time. We also determined that CD52g incorporates into other cells present in the MRT, including human immunodeficiency virus (HIV-1) infected cells (lymphocytes, macrophages) and the parasite, Trichomonas vaginalis (TV), and that HIV virions produced from CD52g-coated cells incorporate CD52g in the virus particle membrane. HCA alone did not agglutinate HIV or TV. Both pathogens, however, appeared to co-agglutinate with sperm when co-cultures were treated with HCA. The trapping of pathogens in sperm agglutinates resulted in decreased TV adherence to MatTek tissue and vaginal epithelial cells, and a modest neutralization of HIV-1 in TZM-bl assays. These data indicate that HCA is a promising candidate to achieve contraception and decrease the male-to-female transmission of STI pathogens.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Molecular and Translational Medicine
Grantor
Boston University
Year dc:date.issued
2020

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Baldeon Vaca, Gabriela Betsave
Advisors dc:contributor.advisor
  • Anderson, Deborah
  • Sagar, Manish
ORCID dc:identifier.orcid

Subjects

dc:subject × 7

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/39394

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Baldeon Vaca, Gabriela Betsave. Topical use of monoclonal antibodies as a multipurpose prevention technology offering contraception and decreased transmission of HIV-1 and trichomonas vaginalis. doctoral thesis, Boston University, 2020. https://hdl.handle.net/2144/39394